Clinical Trial Update: Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating daratumumab in combination with dexamethasone for resistant or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: University Hospital, Lille | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED